Athernal Bio
Startup
Athernal Bio is developing targeted immunotherapies to treat blood cancer precursor conditions before cancers become established. The company’s primary focus is high-risk clonal haematopoiesis (CH), a widespread precursor which can lead to acute myeloid leukaemia and other haematological cancers. High-risk CH affects multiple groups, including patients with rare blood disorders, cancer survivors, and the ageing population. Athernal Bio’s initial programme will target an orphan indication in patients with rare blood disorders, associated with aggressive and highly accelerated CH.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events